Latest Patents News

Page 16 of 104
Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.
Ada Torres
Ada Torres
31 July 2026
Impact Minerals pushes its Lake Hope High Purity Alumina project into pilot production while its JV partner Kuniko hits mineralisation in every hole at Commonwealth, discovering new high-grade extensions.
Maxwell Dee
Maxwell Dee
31 July 2026
Sparc Technologies has secured commercial traction for its graphene additive ecosparc® with major coatings players AkzoNobel and Petro Vietnam Paint, launched a new additive range for electrostatic coatings, and marked six months of continuous operation at its green hydrogen pilot plant.
Victor Sage
Victor Sage
31 July 2026
Talga Group has marked a milestone with its first commercial delivery of natural graphite anode outside Asia, progressing key funding discussions and strategic partnerships to support its Vittangi Anode Project.
Maxwell Dee
Maxwell Dee
30 July 2026
Zelira Therapeutics has raised nearly US$33 million into its HOPE® 1 special purpose vehicle, valuing the SPV at about US$66 million post-money. The funds will advance FDA regulatory submissions and Phase 1 clinical trials for its autism-targeting cannabinoid drug.
Ada Torres
Ada Torres
30 July 2026
Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial stays on track for November topline results, buoyed by strong open-label extension enrolment and aligned EMA-FDA regulatory advice. A new antidepressant study publication and fresh patents add momentum, supported by a $16.7 million cash runway to mid-2027.
Ada Torres
Ada Torres
30 July 2026
Mesoblast delivered US$115 million in Ryoncil® revenue in its first full year post-FDA approval, while expanding clinical trials into adult indications and acquiring cutting-edge CAR technology to boost its cell therapy pipeline.
Ada Torres
Ada Torres
30 July 2026
Island Pharmaceuticals has marked a major step forward in its antiviral program with the start of GMP manufacturing for Galidesivir, expanded USAMRIID collaboration, and FDA orphan drug designation. Regulatory approvals for compassionate use in Uganda’s Ebola outbreak and a new dose optimisation study with Texas Biomed further de-risk the pathway to approval.
Victor Sage
Victor Sage
30 July 2026
Dimerix Limited (ASX: DXB) has inked its fifth regional licensing agreement with Everest Medicines, boosting potential milestone payments to A$1.9 billion and expanded its kidney disease pipeline through the acquisition of DMX-652. The Phase 3 ACTION3 trial for DMX-200 remains statistically robust, with funding secured to advance both clinical programs.
Ada Torres
Ada Torres
30 July 2026
Parkway Corporate delivered a record $7.25 million quarterly revenue and $0.54 million EBITDA, powered by a major water infrastructure contract. The company progressed key approvals for its Queensland Brine Management Complex and struck a strategic collaboration with Hitachi to develop advanced brine concentration technology.
Victor Sage
Victor Sage
30 July 2026
Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.
Ada Torres
Ada Torres
29 July 2026
Amplia Therapeutics reported encouraging mature data from its ACCENT trial, initiated a Phase 2b pancreatic cancer study, launched an ovarian cancer trial, and refreshed its board leadership while maintaining a solid cash balance of A$24 million.
Victor Sage
Victor Sage
29 July 2026

Browse the archive

Full archive